Results 181 to 190 of about 14,552,787 (242)
RETRACTION: Effect of Mitomycin C and 5-Fluorouracil on Wound Healing in Patients Undergoing Glaucoma Surgery: A Meta-Analysis. [PDF]
Int Wound Jeuropepmc +1 more source
European Journal of Ophthalmology, 2010 Purpose Mitomycin C after photorefractive keratectomy (PRK) is used to reduce the development of haze and regression in higher intended corrections. The aim of this study was to investigate the safety, stability, and efficacy of EpiLASIK with mitomycin C.
Christoph, Winkler von Mohrenfels +3 more
core +4 more sources
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Cancer Treatment Reviews, 1976
Summary Preclinical 1. Mitomycin C is an alkylating agent requiring reduction of the quinone to be active. 2. The aziridine ring is essential for the antitumor activity of mitomycin C. 3. The degree of DNA cross-linking and tumor inhibition is proportional to the guanine and cytosine content of the DNA. 4.
S T, Crooke, W T, Bradner
openaire +2 more sources
Summary Preclinical 1. Mitomycin C is an alkylating agent requiring reduction of the quinone to be active. 2. The aziridine ring is essential for the antitumor activity of mitomycin C. 3. The degree of DNA cross-linking and tumor inhibition is proportional to the guanine and cytosine content of the DNA. 4.
S T, Crooke, W T, Bradner
openaire +2 more sources
Cancer chemotherapy and biological response modifiers, 1990
The mitomycins are antitumor antibiotics that are under investigation now for more than 30 years. Mitomycin C (MMC) is the best investigated subtype. It serves as a prototype for drugs with bioreductive alkylation, which is a unique feature of this class. MMC is mainly active under anaerobic circumstances.
J, Den Hartigh, J, Verweij, H M, Pinedo
+9 more sources
The mitomycins are antitumor antibiotics that are under investigation now for more than 30 years. Mitomycin C (MMC) is the best investigated subtype. It serves as a prototype for drugs with bioreductive alkylation, which is a unique feature of this class. MMC is mainly active under anaerobic circumstances.
J, Den Hartigh, J, Verweij, H M, Pinedo
+9 more sources
Impact of Mitomycin-C Application Time on the Scleral Mitomycin-C Concentration
Journal of Ocular Pharmacology and Therapeutics, 2001The aim of this study was to determine the effect of varying the application time of Mitomycin-C (MMC) on the scleral concentration of MMC. The sclerae of 14 human donor eyes were used for this study. The episcleral sides of the 4 scleral quadrants of each donor eye were exposed for 0.5, 1, 3 and 5 min to round, 8 mm-diameter sponges soaked with 50 ...
C, Vass +4 more
openaire +2 more sources
Mitomycin C (z.B. Mitomycin C „Kyowa“)
2006aufgrund zahlreicher Berichte uber Nekrosen wird Mitomycin C als gewebsnekrotisierend ...
openaire +1 more source
Bacteriocidal action of mitomycin C
Biochimica et Biophysica Acta, 1960Abstract The bacteriocidal action of Mitomycin C has been investigated with respect to its biochemical, genetic and morphological correlates. All findings are consistent with the observation that cells treated with Mitomycin lose DNA, but not RNA or protein, to the surrounding medium.
E, REICH, A J, SHATKIN, E L, TATUM
openaire +3 more sources
Mitomycin C in Photorefractive Keratectomy
Journal of Refractive Surgery, 2009Purpose: To evaluate the outcome of primary or retreatment photorefractive keratectomy (PRK) or photo-therapeutic keratectomy (PTK) with mitomycin C (MMC) 0.02% applied prophylactically intraoperatively for the prevention of haze and regression in cases of significant haze and regression after primary PRK, due to previous ...
Ashraf, Shalaby +2 more
openaire +2 more sources
American Journal of Clinical Oncology, 1984
The clinical spectrum and the pathological findings of renal toxicity in four patients treated with mitomycin-C are described. Our experience and evidence in the literature indicates that the renal impairment appears to be total-dose-related, with most patients developing renal symptoms after receiving at least 60 mg of mitomycin-C.
T S, Ravikumar +3 more
openaire +2 more sources
The clinical spectrum and the pathological findings of renal toxicity in four patients treated with mitomycin-C are described. Our experience and evidence in the literature indicates that the renal impairment appears to be total-dose-related, with most patients developing renal symptoms after receiving at least 60 mg of mitomycin-C.
T S, Ravikumar +3 more
openaire +2 more sources
Reductive activation of mitomycin C
Biochemistry, 1988Mitomycin C, an antitumor antibiotic, is known to require reductive activation in order to function as an alkylating agent. In this work reduction has been carried out by using radiolytically produced formate radicals that reduce mitomycin C to its semiquinone in a clean rapid one-electron reaction.
B M, Hoey, J, Butler, A J, Swallow
openaire +2 more sources